Orchid Pharma Ltd

Orchid Pharma Ltd has filed a Statement of Deviation or Variation for the quarter ended June 30, 2026, regarding the use of proceeds from its Qualified Institutional Placement (QIP). The company raised ₹400 Crores on June 27, 2023. A deviation in fund utilization was noted and approved by shareholders on September 20, 2025. The modification in allocation is due to changes in the business environment and strategic requirements, leading to the postponement of the 'new block at API Facility' project. Proceeds originally allocated to this project have been reallocated to mitigate financial burdens and ensure optimal utilization. The Audit Committee has reviewed the statement.

Orchid Pharma Ltd has submitted its Monitoring Agency Report for Q1 FY27 (ended June 30, 2026), prepared by CARE Ratings Limited. The report confirms that the utilization of proceeds from the Qualified Institutions Placement (QIP) of ₹400 crores has no deviation from the stated objects. The company revised the allocation of QIP proceeds among the objects, and the monitoring agency has reviewed this in relation to the QIP's objectives. The report is in compliance with SEBI regulations.

Orchid Pharma Ltd announced its unaudited financial results for the first quarter of FY2026-27 ended June 30, 2026. The company reported a Profit After Tax of ₹1,193.72 lakhs on a standalone basis. The Board of Directors approved these results, along with the auditors' review reports. The filing also detailed the impact of the amalgamation with Dhanuka Laboratories Limited, effective from April 01, 2024, and the completion of acquisitions related to Allecra Therapeutics and Orchid Pharma Europe GmbH. The company continues to monitor developments regarding new labor codes.

Orchid Pharma Ltd announced that its Board of Directors, in a meeting held on August 14, 2026, approved the unaudited financial results for the first quarter of the Financial Year 2026-27, ending June 30, 2026. The results, which were subject to a limited review by statutory auditors M/s. Singhi & Co., were presented on both standalone and consolidated bases. The company also noted the amalgamation with Dhanuka Laboratories Limited, effective July 10, 2026, with an appointed date of April 01, 2024, impacting the restatement of financial results. Additionally, the company completed the acquisition of assets of Allecra Therapeutics GmbH and Allecra Therapeutics SAS, consolidating global ownership of Enmetazobactam.

Orchid Pharma Ltd has announced that its Board of Directors will convene on August 14, 2026, to consider and approve the Unaudited Limited Reviewed Financial Results for the first quarter of the Financial Year 2026-27, ending June 30, 2026. The meeting will also review Restated Audited Standalone & Consolidated Financial Results for the quarter and financial year ended March 31, 2026, along with related statements and revised auditors' reports, due to a Scheme of Amalgamation. The trading window for company securities remains closed from July 1, 2026, until 48 hours after the declaration of the Q1 FY27 results.

Orchid Pharma Ltd's Board of Directors has approved the issuance and allotment of 4,45,86,052 fully paid-up equity shares of Rs. 10 each to eligible shareholders of Dhanuka Laboratories Limited. This allotment is pursuant to the scheme of Amalgamation, with the shares proposed to be listed on BSE and NSE. Following the allotment and cancellation of cross-holding, the company's paid-up share capital has increased to Rs. 59,88,52,000, comprising 5,98,85,200 equity shares. The record date for this allotment was July 23, 2026.

Orchid Pharma Ltd's Board of Directors has approved the issuance and allotment of 4,45,86,052 fully paid-up equity shares of Rs. 10 each to eligible shareholders of Dhanuka Laboratories Limited. This allotment is pursuant to a scheme of Amalgamation, with the record date set as July 23, 2026. The newly issued shares will be listed and traded on BSE and NSE, ranking pari-passu with existing equity shares. Following the allotment and cancellation of cross-holdings, the company's paid-up share capital has increased to Rs. 59,88,52,000, divided into 5,98,85,200 equity shares.

Orchid Pharma Ltd has scheduled a Board of Directors meeting for August 1, 2026, to consider and approve the allotment of fully paid-up equity shares. This allotment is part of the amalgamation scheme where Dhanuka Laboratories Limited will merge with Orchid Pharma Limited. Eligible shareholders of Dhanuka Laboratories as of the record date, July 23, 2026, will receive these shares. This meeting follows a prior intimation dated July 10, 2026, and complies with SEBI's listing regulations.

Orchid Pharma Limited has announced an upcoming investor roadshow where Whole Time Director Mr. Mridul Dhanuka will participate. The roadshow is scheduled to take place in Singapore from Wednesday, July 29, 2026, to Friday, July 31, 2026. The meetings will be conducted in a physical group format. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during these interactions. Investors are advised that the schedule is subject to change due to unforeseen circumstances.

Orchid Pharma Ltd has fixed Thursday, July 23, 2026, as the record date for allotting shares to the shareholders of Dhanuka Laboratories Limited, following the scheme of amalgamation. The scheme became effective on July 10, 2026, with Dhanuka Laboratories dissolving without winding up. The appointed date for the amalgamation is April 1, 2024. Orchid Pharma's authorized share capital has been increased to ₹164.51 crore. The share exchange ratio is 161 Orchid Pharma shares for every 5 Dhanuka Laboratories shares.